InvestLog
NYXH Nyxoah S.A. logo

NYXH Nyxoah S.A.

Healthcare
$2.87+0.00%ClosedMarket Cap: $107.2M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

2.96

P/S

5.64

EV/EBITDA

-1.37

DCF Value

$-78.30

FCF Yield

-79.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

48.3%

Operating Margin

-527.2%

Net Margin

-527.8%

ROE

-164.4%

ROA

-87.9%

ROIC

-116.2%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$7.4M$-18.4M$—
Q4 null$5.6M$-23.5M$—
FY null$10.0M$-90.1M$—
Q3 null$2.0M$-23.6M$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$6.00

Target (Median)

$6.00

Target Range

$5.00 - $7.00

1 Strong Buy3 Buy2 Hold0 Sell0 Strong Sell
Piper SandlerOverweight
2026-05-13
StifelHold
2026-05-12
StifelBuy
2026-04-10
Cantor FitzgeraldOverweight
2026-03-23
StifelBuy
2026-01-29

Company Info

Sector

Healthcare

Industry

Medical - Instruments & Supplies

Country

BE

Exchange

—

Beta

0.88

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Peers

CATX logoCATXGNFT logoGNFTIVVD logoIVVDKRMD logoKRMDOABI logoOABIOSUR logoOSURPRE logoPRESTIM logoSTIMTARA logoTARAUTMD logoUTMD